$14,139 Mln
$--
62.49
As on 22-Sep-2023 16:10 EDT
$-0.06
•
-0.24%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Smith & Nephew SNATS - ADR
| -5.69 | -7.21 | -19.06 | 9.74 | -12.30 | -7.22 | 0.21 |
|
S&P BSE Sensex
| 8.49 | 1.22 | 3.91 | 11.02 | 20.17 | 12.37 | 12.54 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
Smith & Nephew SNATS - ADR
| -22.33 | -16.21 | -10.40 | 30.84 | 8.85 | 18.57 | -13.93 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Smith & Nephew SNATS Inc. - ADR stood at $ 9,966 Mln as on 31-Dec-22
The share price of Smith & Nephew SNATS Inc. - ADR is $25.360000 (NYSE) as of 22-Sep-2023 16:10 EDT. Smith & Nephew SNATS Inc. - ADR has given a return of -12.3% in the last 3 years.
Smith & Nephew SNATS Inc. - ADR has a market capitalisation of $ 14,139 Mln as on 19-May-2023. As per Value Research classification, it is a company.
The P/B ratio of Smith & Nephew SNATS Inc. - ADR is 2.25 times as on 19-May-2023, a -0.44% premium to its peers’ median range of 4.02 times.
The P/E ratio of Smith & Nephew SNATS Inc. - ADR is 62.49 times as on 19-May-2023, a -0.7% premium to its peers’ median range of 207.27 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Smith & Nephew SNATS Inc. - ADR and enter the required number of quantities and click on buy to purchase the shares of Smith & Nephew SNATS Inc. - ADR.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
The CEO & director of Ms. Anne-Francoise Nesmes. is Smith & Nephew SNATS Inc. - ADR, and CFO & Sr. VP is Dr. Deepak S. Nath Ph.D..
The promoters of Smith & Nephew SNATS Inc. - ADR have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
380
|
|
|
311
|
|
|
91
|
|
|
90
|
| Smith & Nephew SNATS Inc. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
4.12
|
|
Return on capital employed(%)
|
2.62
|
|
Debt-to-equity ratio
|
0.55
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Smith & Nephew SNATS Inc. - ADR was No Profit.
$14,139.13 Mln
$--
$--
$0.00 Mln
$--
High
$21.78 - 33.09
436,686,016
NYSE: SNN
Watford
https://www.smith-nephew.com
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT,... and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
